weight loss drugs
Americans Are Conflicted on the Long-Term Effects of GLP-1s, Data Shows
While Americans see the benefits of GLP-1s, skepticism about relying on an injection to lose weight still runs deep, a new survey finds.
GLP-1s Are Most Popular in These US Cities, Report Finds
Search trends and survey data show where interest in weight loss drugs like Ozempic and Wegovy is surging in America.
Noom Launches $119 Microdose GLP-1 Weight Loss Program
Noom’s microdose GLP-1 program says 70% of users report no side effects and lose up to 17 pounds in 60 days with behavior change support.
Is the Fitness Industry Seizing Its GLP-1 Opportunity?
At the ATN Summit, fitness leaders weighed how gyms can stay relevant in the GLP-1 era by focusing on accountability and long-term health.
Ozempic’s Biggest Fans? It’s Not Gen Z
A new survey from AlynMD reveals shifting attitudes toward weight loss medications like Ozempic and which generation is most on board.
Post-Hims & Hers Breakup, Novo Nordisk Strengthens WeightWatchers Ties
With a pharma giant in its corner, WeightWatchers is mounting a comeback, relying on FDA-approved GLP-1 medications.
Wegovy Partnership Unravels as Novo Nordisk, Hims & Hers Trade Accusations
Novo Nordisk ends its Wegovy deal with Hims & Hers, citing safety concerns as the telehealth firm pushes back.
New Partnership Brings WeightWatchers GLP-1 Program to UK
WeightWatchers partners with U.K.-based CheqUp to expand GLP-1 support, following news of its Chapter 11 and focus on long-term growth.
ISSA Launches GLP-1 Support Course for Trainers
ISSA launches a GLP-1 support course to help fitness pros guide clients through weight loss, behavior change and long-term health success.
Zepbound Trumps Wegovy in Weight Loss Showdown, Study Finds
Zepbound helped patients lose more weight than Wegovy in a 72-week trial, with greater reductions in both body weight and waist size.
